Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
Hong Xiang, Lucy Liu, Yuying Gao, Ago Ahene, Monica Macal, Amy W Hsu, Lyndah Dreiling, Helen Collins, Hong Xiang, Lucy Liu, Yuying Gao, Ago Ahene, Monica Macal, Amy W Hsu, Lyndah Dreiling, Helen Collins
Abstract
Purpose: To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth factor receptor 2b antibody, bemarituzumab.
Methods: Nonlinear mixed-effect modeling was used to analyse PK data. In vitro binding affinity and receptor occupancy of bemarituzumab were determined. Simulation was conducted to estimate dose and schedule to achieve an empirical target Ctrough in a phase 2 trial (FIGHT, NCT03694522) for patients receiving first-line treatment combined with modified 5-fluourouracil, oxaliplatin and leucovorin (mFOLFOX6) for gastric and gastroesophageal junction adenocarcinoma.
Results: Bemarituzumab PK is best described by a two-compartment model with parallel linear and nonlinear (Michaelis-Menten) elimination from the central compartment. Albumin, gender, and body weight were identified as the covariates on the linear clearance and/or volume of distribution in the central compartment, and no dose adjustment was warranted. An empirical target of bemarituzumab Ctrough of ≥ 60 µg/mL was projected to achieve > 95% receptor occupancy based on in vitro data. Fifteen mg/kg every 2 weeks, with a single dose of 7.5 mg/kg on Cycle 1 Day 8, was projected to achieve the target Ctrough on Day 15 in 98% of patients with 96% maintaining the target at steady state, which was confirmed in the FIGHT trial.
Conclusion: A projected dose and schedule to achieve the target Ctrough was validated in phase 1 of the FIGHT trial which supported selection of the phase 2 dose and schedule for bemarituzumab.
Keywords: Anti-fibroblast growth factor receptor 2b; Bemarituzumab; Dose selection; Gastric and gastroesophageal junction adenocarcinoma; Population PK analysis; Target-mediated clearance.
Conflict of interest statement
H. Xiang, A. Ahene, L. Dreiling, and H. Collins are employed with Five Prime Therapeutics, Inc. and M. Macal and AW Hsu are former Five Prime employees. They have ownership interest in the Five Prime stock. L. Liu and Y. Gao declare no potential conflicts of interest.
Figures
References
- Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239–248. doi: 10.2147/CMAR.S149619.
- Cancer Stat Facts: Esophageal Cancer. National Cancer Institute (2016) .
- Cancer Stat Facts: Stomach cancer. National Cancer Institute (2016) .
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate Date. J Clin Oncol. 2006;24(18):2903–2909. doi: 10.1200/JCO.2005.05.0245.
- Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–2414. doi: 10.3748/wjg.v22.i8.2403.
- Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–129. doi: 10.1038/nrc2780.
- Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2) Dev Biol. 1993;158(2):475–486. doi: 10.1006/dbio.1993.1205.
- Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647. doi: 10.1158/-13-0050.
- Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Kim WH, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110(4):967–975. doi: 10.1038/bjc.2013.802.
- Seo S, Park SJ, Ryu MH, Park SR, Ryoo BY, Park YS, Na YS, Lee CW, Lee JK, Kang YK. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget. 2017;8(20):33844–33854. doi: 10.18632/oncotarget.12953.
- Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-Index predicts poor survival. Mod Pathol. 2016;29(9):1095–1103. doi: 10.1038/modpathol.2016.96.
- Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106(4):727–732. doi: 10.1038/bjc.2011.603.
- Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol. 2012;43(10):1559–1566. doi: 10.1016/j.humpath.2011.12.002.
- Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020 doi: 10.1200/JCO.19.01834.
- Alsina M, Gullo I, Carneiro F. Intratumoral heterogeneity in gastric cancer: a new challenge to face. Ann Oncol. 2017;28(5):912–913. doi: 10.1093/annonc/mdx134.
- Deshpande AM, Palencia S, Bellovin DI, Gemo AT, Giese T, Stohr B, Pierce KL, Los G. Expression of FGFR2b in gastric cancer as measured by immunohistochemistry with a highly specific monoclonal antibody. Cancer Res. 2014;74(19 Suppl):2845. doi: 10.1158/1538-7445.AM2014-2845.
- Ji Y, Jin JY, Hyman DM, Kim G, Suri A. Challenges and opportunities in dose finding in oncology and immuno-oncology. Clin Trans Sci. 2018;11(4):345–351. doi: 10.1111/cts.12540.
- Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004;9(Suppl 1):36–42. doi: 10.1634/theoncologist.9-suppl_1-36.
- Leyland-Jones B, Arnold A, Gelmon K, Verma S, Ayoub J-P, Seidman A, Dias R, Howell J, Rakhit A. Pharmacologic insights into the future of trastuzumab. Ann Oncol. 2001;12(Suppl. 1):S43–S47. doi: 10.1093/annonc/12.suppl_1.s43.
- Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmcol. 2014;78(1):106–117. doi: 10.1111/bcp.12323.
- Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006;72(1):1–10. doi: 10.1016/j.bcp.2005.12.041.
- Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35(5):573–591. doi: 10.1007/s10928-008-9102-8.
- Thomas VA, Balthasar JP. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies. 2019;8(4):56. doi: 10.3390/antib8040056.
- Tejani MA, Cheung E, Eisenberg PD, Scott AJ, Tesfaye AA, Dreiling L, Eng C, Marina N, Mitra S, Xiang H, et al. Phase 1 results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC) J Clin Oncol. 2019;37:91–91. doi: 10.1200/JCO.2019.37.4_suppl.91.
- Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008;48(3):267–278. doi: 10.1177/0091270007313393.
- Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, Rodriguez R, Chow A. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol. 2009;49(10):1142–1156. doi: 10.1177/0091270009344989.
- Xin Y, Bai S, Damico-Beyer LA, Jin D, Liang WC, Wu Y, Theil FP, Joshi A, Lu Y, Lowe J, et al. Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res. 2012;29(9):2512–2521. doi: 10.1007/s11095-012-0781-x.
- Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gradreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779–786. doi: 10.1007/s00280-007-0664-8.
- Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, et al. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol. 2014;74(4):819–829. doi: 10.1007/s00280-014-2560-3.
- Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Therap. 2018;103(4):631–642. doi: 10.1002/cpt.982.
- Wang E, Kang D, Bae KS, Marshall MA, Pavlov D, Parivar K. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. J Clin Pharmacol. 2014;54(10):1108–1116. doi: 10.1002/jcph.309.
- Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol. 2001;12:S49–S55. doi: 10.1093/annonc/12.suppl_1.s49.
- Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. PNAS. 2006;103(11):4005–4010. doi: 10.1073/pnas.0508123103.
- Genentech Inc . HERCEPTIN® (trastuzumab) [Package insert] South San Francisco: Genentech Inc; 2010.
Source: PubMed